meningococcal b

Meningococcal B: What You Need to Know as Cases Rise in Australia

In the past few weeks, South Australia has found itself at the centre of a concerning health story involving meningococcal disease — specifically, the rare but serious strain known as meningococcal B. The tragic death of an Adelaide chef’s nephew while travelling abroad and another fatal case involving a Perth university student have sparked renewed public attention on this often-overlooked illness.

While meningococcal disease can be frightening, understanding what it is, how it spreads, and what Australians can do to protect themselves is key to staying safe — especially during peak travel and social seasons.

What Is Meningococcal B?

Meningococcal B is one of several types of meningococcal disease caused by the bacterium Neisseria meningitidis. Unlike meningococcal C (which was largely eradicated thanks to Australia’s successful immunisation program), meningococcal B remains the most common type circulating in Australia today.

The bacteria primarily infect the bloodstream or lining around the brain and spinal cord, leading to potentially life-threatening conditions such as meningitis (infection of the protective membranes covering the brain) and septicaemia (blood poisoning). Symptoms can develop rapidly and include fever, headache, stiff neck, nausea, vomiting, sensitivity to light, and sometimes a rash that doesn’t fade when pressed — a sign known as the “non-blanching rash”.

Unlike other forms, meningococcal B is particularly sneaky because it doesn’t always present with a distinctive rash, making early diagnosis difficult. And because it spreads through close contact (like sharing utensils, kissing, or living in crowded spaces), outbreaks can occur quickly among students, young adults, or even within households.

Recent Tragic Cases Spark National Attention

The recent wave of concern began with news from South Australia. In early 2025, chef-to-the-Crows Chris Jauncey publicly shared his heartbreak after his nephew died from meningococcal B while visiting Europe. According to reports from Adelaide Now and 7NEWS, the young man fell ill shortly after boarding a flight and passed away within hours of arrival. His uncle’s emotional plea for awareness went viral across Australian media.

Just days later, another devastating case made headlines: a 21-year-old Perth university student died from a sudden meningococcal infection after falling ill mid-flight. The speed of his decline shocked both his family and local health authorities. As per The Times of India, he collapsed onboard and was pronounced dead upon landing — a scenario that underscores how rapidly the disease can progress.

These cases are not isolated. According to the Australian Government Department of Health, meningococcal B accounted for nearly half of all notified cases in 2023, marking a slight increase compared to previous years. While fatalities remain relatively low overall, each loss is deeply felt — and serves as a stark reminder that prevention truly matters.

Why Are We Hearing About This Now?

Experts suggest that increased international travel post-pandemic may play a role in recent cases. Young Australians returning from overseas are more likely to encounter different strains of the bacteria, some of which aren’t covered by standard vaccines used in Australia.

Additionally, universities and student communities — where people live in close quarters — remain high-risk environments. A 2022 outbreak at an Australian university led to multiple cases and prompted emergency vaccination campaigns, showing how easily the disease can spread in dormitories or shared housing.

Public health officials say these latest tragedies highlight a persistent gap in awareness around meningococcal B. Unlike meningococcal ACWY (which is widely promoted and routinely offered to teenagers), there is no national school-based vaccine program for meningococcal B. Instead, protection relies on catch-up doses for high-risk groups — including infants, adolescents, and those with certain medical conditions.

How Is Meningococcal Disease Treated and Prevented?

Treatment:
If diagnosed early, meningococcal disease can be treated with antibiotics. However, due to its rapid onset, many patients arrive too late for effective intervention. Supportive care in intensive units is often required, but survival depends heavily on how quickly treatment begins.

Prevention:
The best defence is vaccination. In Australia, two vaccines protect against meningococcal B:
- Bexsero® (GSK)
- Trumenba® (Pfizer)

Both are available under the National Immunisation Program for specific age groups:
- Infants receive Bexsero® at 2, 4, and 6 months, with a booster at 12 months.
- Adolescents aged 13 to 15 may receive a free dose through school programs.
- Catch-up doses are recommended for individuals up to age 20 who haven’t been vaccinated.

For those heading overseas — especially to parts of Africa, Asia, or Europe where outbreaks have occurred — consulting a travel health clinic about additional precautions is strongly advised.

Dr. Sarah Thompson, a communicable diseases specialist at SA Health, explains:

“We’ve seen meningococcal B become increasingly common in young adults. While it’s not as contagious as the common cold, it moves fast and can kill within 24 hours. Vaccination is your strongest shield.”

What’s Being Done in South Australia?

Following the recent cases, SA Health issued a public warning encouraging parents and travellers to recognise symptoms and seek urgent medical help if concerned. They also reminded healthcare providers to consider meningococcal disease in differential diagnoses, particularly for sudden fevers without obvious cause.

The government has reiterated its support for existing immunisation schedules but stopped short of calling for a universal school-based Bexsero® rollout — citing cost and prioritisation debates within federal health policy.

However, advocacy groups like Meningitis Centre Australia argue that more needs to be done. “Every child or young adult lost to meningococcal B is preventable,” said spokesperson Liam O’Reilly. “Australia leads the world in many areas of public health — we should lead here too.”

A Broader Picture: Trends and Risks in Australia

Historically, Australia has had one of the lowest rates of invasive meningococcal disease globally, thanks to targeted vaccination efforts. But since the introduction of meningococcal C vaccines in 2003, the proportion of B cases has risen steadily.

Data from the National Notifiable Diseases Surveillance System (NNDSS) shows:
- In 2023, 294 cases were reported nationally — up from 256 in 2022.
- Over 80% were meningococcal B.
- Most cases occurred in children under 5 and adolescents/young adults aged 15–24.

Outbreaks are rare but possible — especially during sporting events, festivals, or university semesters. In 2012, a meningococcal B outbreak at a Melbourne music festival resulted in three hospitalisations and heightened calls for better preparedness.

Despite this, funding for research into new vaccines and improved diagnostics remains limited compared to other infectious diseases.

Who Should Get Vaccinated?

While routine vaccination covers many at risk, others may benefit from extra protection:

Private clinics offer both Bexsero® and Trumenba®, though Trumenba® requires three doses and is more expensive.

Looking Ahead: Can We Do Better?

Health experts agree that awareness is the first step. “People don’t think about meningococcal B because they associate it with rashes and fever,” says Dr. Thompson. “But it can strike anyone, anywhere — and it kills fast.”

Calls for expanded access to meningococcal B vaccines are growing louder. Some states, including Queensland, already fund free doses for university entrants — a model that could spread nationwide.

Meanwhile, researchers are exploring next-generation vaccines and rapid diagnostic tools to detect the disease in emergency settings. Public-private partnerships are also being explored to improve surveillance and response times.

For now, the message remains clear: stay informed, get vaccinated if eligible, and trust your instincts. If someone you know suddenly becomes very unwell — especially with fever and confusion — call triple zero (000) immediately.

Key Takeaways

• Meningococcal B is the most common strain in Australia and can be deadly.
• Symptoms develop rapidly; early recognition saves lives.
• Vaccination is safe, effective, and widely available.
• Recent deaths in Adelaide and Perth highlight ongoing risks, especially among young adults.
• Increased travel and close-contact living raise exposure risks.
• Advocacy continues for broader vaccine access and public education.

As summer approaches and Australians prepare for holidays and reunions, health authorities urge vigilance. One missed symptom could mean everything.

For more information, visit